CSS
PRLD icon

Cubist Systematic Strategies’s Prelude Therapeutics PRLD Stock Holding History

Cubist Systematic Strategies’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,102
Closed -$83K – 3444
2024
Q3 		$83K Buy
+40,102
New +$186K ﹤0.01% 2718
2023
Q2 		– Sell
-8,778
Closed -$50K – 4144
2023
Q1 		$50K Buy
+8,778
New +$53.5K ﹤0.01% 3560
2022
Q3 		– Sell
-39,938
Closed -$208K – 4662
2022
Q2 		$208K Buy
+39,938
New +$203K ﹤0.01% 3671
2022
Q1 		– Sell
-116,303
Closed -$1.45M – 3730
2021
Q4 		$1.45M Buy
116,303
+94,548
+435% +$1.54M 0.01% 1637
2021
Q3 		$680K Buy
21,755
+4,558
+27% +$148K 0.01% 1817
2021
Q2 		$492K Buy
17,197
+10,802
+169% +$385K 0.01% 2023
2021
Q1 		$277K Buy
+6,395
New +$424K ﹤0.01% 2302
2020
Q4 		– Sell
-100
Closed -$3K – 2679
2020
Q3 		$3K Buy
+100
New +$2.82K ﹤0.01% 2455

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cubist Systematic Strategies's PRLD Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 40,102 shares — an estimated $83K sold.

Cubist Systematic Strategies first reported a position in PRLD in Q3 2020 and held it in 8 quarters. The position peaked at $1.45M in Q4 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Cubist Systematic Strategies reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 40,102 Prelude Therapeutics shares in Q4 2024, an estimated $83K.
  • Cubist Systematic Strategies first reported a position in Prelude Therapeutics in Q3 2020 and held it in 8 quarters.
  • Cubist Systematic Strategies's Prelude Therapeutics position peaked at $1.45M in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.